Case Study: Nanyang Biologics accelerates drug discovery by 68% with Equinix AI-ready data centers

Nanyang Biologics harnesses AI to unlock therapeutic potential in natural compounds

Nanyang Biologics, a Singapore-based biotech company, wanted to speed drug discovery by screening hundreds of thousands of plant-derived compounds and predicting their bioactivity, but its AI-driven DTIGN platform required powerful GPUs, high-performance connectivity, and scalable infrastructure. Equinix helped support this challenge with AI-ready data centers and high-speed interconnection for the company’s resource-intensive AI workloads.

Using Equinix AI-ready data centers, Internet Access, and a global digital ecosystem, Nanyang Biologics scaled its DTIGN platform to analyze two billion natural compounds more efficiently and collaborate with research partners more easily. Equinix-enabled infrastructure is expected to accelerate drug discovery by 68%, improve bioactivity prediction accuracy by 27%, and reduce R&D costs by 90%.

Nanyang Biologics

Giang Nguyen

Chief Technology Officer